No limits: NewLimit lands $435m ahead of human trials
The longevity biotech is accelerating toward the clinic after uncovering a promising age-reprogramming therapy years sooner than expected.…
3D human liver reconstruction reveals changes in cirrhosis
March 10, 2026 At a Glance A new 3D reconstruction of human liver tissue shows the organ’s complex…
NewLimit ‘close’ to clinic-ready epigenetic reprogramming therapy
Liver rejuvenation program produces a ‘lead payload’ as biotech begins its journey towards human clinical trials. After several…